FDA Brief

Warning letters Food

FDA warning letter to

SafaLab, Inc.

High riskIssued Feb 18, 2021Posted Mar 4, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA and FTC warned SafaLab over unapproved, misbranded COVID-19 drug claims for The Prevention 12 Pak supplements.

What happened

FDA and FTC reviewed SafaLab's websites www.safalab.com and www.weeksmd.com on February 8, 2021. FDA found that www.safalab.com offered The Prevention 12 Pak—a set of 12 supplements—for sale in the U.S. with claims that it could mitigate, prevent, treat, diagnose, or cure COVID-19, and www.weeksmd.com directed consumers to safalab.com to buy it. FDA said the product is an unapproved new drug and a misbranded drug.

What FDA found

  1. FDA says the product is an unapproved new drug—a drug sold without FDA approval—because it was sold with claims to prevent or treat COVID-19.

    Federal Food, Drug, and Cosmetic Act section 505(a), 21 U.S.C. § 355(a)
  2. FDA says the product is a misbranded drug—a drug with misleading labeling—because its labeling made misleading COVID-19 prevention or treatment claims.

    Federal Food, Drug, and Cosmetic Act section 502, 21 U.S.C. § 352
  3. Introducing the product into interstate commerce is prohibited.

    Federal Food, Drug, and Cosmetic Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)
  4. The FTC Act prohibits advertising that a product can prevent, treat, or cure human disease without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. 41 et seq.

What FDA wants

FDA asks SafaLab to immediately stop selling any unapproved, unauthorized COVID-19 products and to email CFSAN and CDER within 48 hours describing the specific steps taken and how recurrence will be prevented. FTC separately asks for an email within 48 hours to Richard Cleland describing actions taken to address its concerns.

Who should pay attention

  • dietary supplement companies making health claims
  • online retailers and marketplaces selling COVID-19 products
  • consumers considering COVID-19 prevention supplements

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk